SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent
NCT07494994 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2026-08-26
Summary
Informed consent is an ethical and legal component of the pre-procedural process. Informed consent involves the explanation of procedural steps and discussion regarding the risks, benefits, and alternatives of the proposed procedure. The current informed consent process lacks standardization, and patient experience can vary widely depending on the provider obtaining consent. This pilot study aims to ensure high quality informed consent for patients undergoing a complex oncologic operation known as a pancreaticoduodenectomy (Whipple operation), through the creation of an educational video as a method of obtaining informed consent. This study will explore whether the application of an educational video as part of the informed consent process increases patient understanding, comfort, and overall satisfaction throughout the Whipple operative course. The primary objective of this study is to determine whether implementation of a multimedia video as an enhancement to surgical informed consent improves patient satisfaction, promotes understanding, and informs operative expectations. The desired outcome is to standardize the informed consent process to eliminate variability in the quality of the consent process and to mitigate the impact of healthcare barriers such as health literacy and language proficiency in the informed consent process.
Conditions
- Pancreas Cancer
Interventions
- BEHAVIORAL
-
Standard Informed Consent
Participants receive the institution's standard verbal informed consent discussion delivered by a qualified provider, covering the Whipple operation, expected outcomes, risks, benefits, and alternatives. The provider answers follow-up questions.
- BEHAVIORAL
-
Multimedia Video - Based Informed Consent
Participants view a narrated, animated video explaining the Whipple procedure; benefits, alternatives, and potential perioperative and postoperative complications; and resources for recovery. Afterward, a provider answers questions.
Sponsors & Collaborators
-
UNC Lineberger Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Jen J Yeh, MD · UNC Lineberger Comprehensive Cancer Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-09-30
- Primary Completion
- 2030-01-31
- Completion
- 2030-01-31
Countries
- United States
Study Locations
More Related Trials
-
Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
NCT02707328 ·Status: TERMINATED ·Phase: PHASE1
-
Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas
NCT00003049 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer
NCT01492907 ·Status: COMPLETED ·Phase: PHASE1
-
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
NCT01726582 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT03484299 ·Status: RECRUITING ·Phase: PHASE1
-
Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants
NCT00898482 ·Status: COMPLETED
-
Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer
NCT01893294 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer
NCT02707315 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-
NCT06937996 ·Status: RECRUITING
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
NCT05462496 ·Status: RECRUITING ·Phase: PHASE2
-
Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery
NCT04452461 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
NCT00049348 ·Status: COMPLETED ·Phase: PHASE2
-
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
NCT01739439 ·Status: TERMINATED ·Phase: PHASE1
-
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
NCT04594772 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment
NCT00288925 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
NCT03322995 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
NCT01821612 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
NCT07081360 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
NCT00557492 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
NCT02676349 ·Status: COMPLETED ·Phase: PHASE2
-
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
NCT00402025 ·Status: COMPLETED ·Phase: PHASE1
-
A Supervised Prehabilitation Program for Patients With Pancreatic Cancer
NCT05692323 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
NCT00005926 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
NCT01146054 ·Status: COMPLETED ·Phase: PHASE2
-
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
NCT06807437 ·Status: RECRUITING ·Phase: PHASE3